MiR-6991-3p is identified as a novel suppressor in the expansion and activation of myeloid-derived suppressor cells in hepatoma-bearing mice.
galectin-9
hepatoma
immunosuppression
miR-6991-3p
myeloid-derived suppressor cells
Journal
OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
16
1
2019
pubmed:
16
1
2019
medline:
16
1
2019
Statut:
epublish
Résumé
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of cells derived from bone marrow, which has a significant ability in inhibition of immune cell response. In this study, the role of miR-6991-3p in regulating function of MDSCs was investigated. MDSCs were isolated from different tissues of the control and hepatoma-bearing mice, and then expression of miR-6991-3p was detected with qPCR. Then, the miR-6991-3p mimic and inhibitor were respectively transfected into MDSCs, and behaviors of MDSCs were evaluated, including expansion, apoptosis, and production of inflammatory factors. Furthermore, we explored the underlying mechanism from which miR-6991-3p regulated MDSC functions. Expression miR-6991-3p was markedly decreased in the MDSCs derived from spleen and further decreased in the MDSCs derived from the tumor tissue. MiR-6991-3p mimic transfection suppressed expansion and promoted apoptosis of MDSCs, accompanied by a significant decrease in the production of IL-6 and GM-CSF that are identified as stimulators in MDSC expansion. In contrast, miR-6991-3p inhibitor transfection displayed the opposite effect. miR-6991-3p bound with and negatively regulated expression of LGALS9, a newly identified immune checkpoint gene and activator of STAT3, suppressing production of multiple factors that were customarily used to characterize the activation of MDSCs. MiR-6991-3p-accommodated MDSCs displayed less suppression on T cells, while miR-6991-3p inhibitor enhanced the suppression of MDSCs on T cells. MiR-6991-3p is identified as a novel suppressor in the expansion and activation of myeloid-derived suppressor cells, which may be regarded as a promising target for modulating the function of MDSCs.
Identifiants
pubmed: 30643429
doi: 10.2147/OTT.S185422
pii: ott-12-309
pmc: PMC6314317
doi:
Types de publication
Journal Article
Langues
eng
Pagination
309-317Déclaration de conflit d'intérêts
Disclosure The authors report no conflicts of interest in this work.
Références
Circ Res. 2001 Oct 12;89(8):661-9
pubmed: 11597988
Annu Rev Immunol. 2003;21:807-39
pubmed: 12615893
J Immunol. 2003 Apr 1;170(7):3631-6
pubmed: 12646627
Clin Cancer Res. 2005 Apr 15;11(8):2962-8
pubmed: 15837748
Nat Immunol. 2005 Dec;6(12):1245-52
pubmed: 16286920
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5280-9
pubmed: 17875756
Clin Immunol. 2008 Apr;127(1):78-88
pubmed: 18282810
J Immunol. 2008 Oct 15;181(8):5791-802
pubmed: 18832739
Leukemia. 2010 Apr;24(4):843-50
pubmed: 20200560
PLoS Pathog. 2010 May 06;6(5):e1000882
pubmed: 20463811
J Immunol. 2010 Aug 15;185(4):2273-84
pubmed: 20644162
J Immunol. 2011 Jan 1;186(1):592-601
pubmed: 21135174
Genome Res. 2012 Sep;22(9):1634-45
pubmed: 22955976
Recent Pat Endocr Metab Immune Drug Discov. 2013 May;7(2):130-7
pubmed: 23514536
PLoS One. 2013 Aug 14;8(8):e72488
pubmed: 23967307
Oncoimmunology. 2013 Nov 1;2(11):e26967
pubmed: 24427545
Cancer Immunol Immunother. 2014 Dec;63(12):1285-96
pubmed: 25183171
Target Oncol. 2016 Aug;11(4):469-77
pubmed: 26880697
Mediators Inflamm. 2016;2016:4375120
pubmed: 26997761
Cancer Gene Ther. 2016 Jun;23(6):188-98
pubmed: 27199222
Int Immunopharmacol. 2016 Oct;39:265-272
pubmed: 27497194
Mol Immunol. 2017 Mar;83:62-71
pubmed: 28110209
Oncogene. 2017 Jun 22;36(25):3599-3608
pubmed: 28166197
J Acquir Immune Defic Syndr. 2017 Oct 1;76(2):200-208
pubmed: 28570288
FEBS J. 2017 Aug;284(15):2410-2424
pubmed: 28605567
EBioMedicine. 2017 Aug;22:44-57
pubmed: 28750861
Mol Carcinog. 2018 Mar;57(3):429-439
pubmed: 29215754
Oncogene. 2018 Aug;37(31):4239-4259
pubmed: 29713056
Front Immunol. 2018 Jul 23;9:1699
pubmed: 30083161
J Biol Chem. 1997 Feb 28;272(9):6078-86
pubmed: 9038233